Establishment of Secondary HLH Mouse Model and Effect of Ruxolitinib on Disease Manifestations of Model Mide.
10.19746/j.cnki.issn.1009-2137.2020.04.050
- Author:
Guang-Qiang MENG
1
;
Jing-Shi WANG
1
;
Wen-Yuan LAI
1
;
Yue SONG
1
;
Zhuo GAO
1
;
Shuo MENG
1
;
Jia ZHANG
1
;
Yi-Ni WANG
1
;
Zhao WANG
2
Author Information
1. Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
2. Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China,E-mail: wangzhao@ccmu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Animals;
Disease Models, Animal;
Lymphohistiocytosis, Hemophagocytic;
Mice;
Mice, Inbred C57BL;
Pyrazoles
- From:
Journal of Experimental Hematology
2020;28(4):1376-1380
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To establish a secondary hemophagocytic lymphohistiocytosis(HLH) mouse model, and to investigate the effect of ruxolitinib on the disease manifestation of model mice.
METHODS:Wild type C57BL/6 mice were randomly divided into 4 groups: two groups of mice were intraperitoneally injected with CpG oligodeoxynucleotide 1826 (CpG-ODN1826) every other day to induce HLH, and other two groups were control groups. One group of the CpG-ODN1826 groups and one of the control groups were given ruxolitinib, and other two groups were given the same amount of PBS. Blood samples, serum ferritin and hepatic/spleen weights of experimental mice were detected and serum cytokine levels were measured by ELISA.
RESULTS:Compared with the control groups, the levels of white blood cells, hemoglobin and platelets in the CpG-ODN1826 groups were significantly lower (P＜0.05); and liver/body weight, spleen/body weight, serum ferritin, sCD25, IL-10, IL-1β, IFN-Ƴ, IL-12p70, GM-CSF, TNF-α and IL-18 levels significantly increased (P＜0.05). There was no significant difference in the levels of IL-2, IL-4, IL-5, IL-6, IL-22, IL-13, IL-27 and IL-23 between the two groups (P＞0.05). The spleen in CpG group had disordered internal structure, expanding red pulp and hyperplastic nucleated cells. The liver had severe perivascular inflammations. The spleen/weight of the ruxolitinib-treated mice in the CpG-ODN1826 group was significantly smaller than that of the unapplied ruxolitinib (P＜0.05).
CONCLUSION:The CpG-ODN1826 can induce secondary HLH symptoms in wild type C57BL/6 mice. Ruxolitinib can alleviate the symptoms of splenomegaly in HLH model mice.
